Drug Patents owned by Celator Pharms

1. Drug name - VYXEOS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8431806 CELATOR PHARMS Liposomal formulations of anthracycline agents and cytidine analogs Apr, 2025

(2 years from now)

US8518437 CELATOR PHARMS Lipid carrier compositions with enhanced blood stability Jun, 2026

(3 years from now)

US7850990 CELATOR PHARMS Compositions for delivery of drug combinations Jan, 2027

(4 years from now)

US9271931 CELATOR PHARMS Compositions for delivery of drug combinations Jan, 2027

(4 years from now)

US8022279 CELATOR PHARMS Liposomal formulations of anthracycline agents and cytidine analogs Sep, 2027

(4 years from now)

US8092828 CELATOR PHARMS Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders Apr, 2029

(6 years from now)

US10166184 CELATOR PHARMS Method of lyophilizing liposomes Oct, 2032

(10 years from now)

US10835492 CELATOR PHARMS Method of lyophilizing liposomes Oct, 2032

(10 years from now)

US10028912 CELATOR PHARMS Method of lyophilizing liposomes Sep, 2034

(12 years from now)

Drugs and Companies using CYTARABINE; DAUNORUBICIN ingredient

Treatment: For the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in adults and pediatric patients 1 year and older; Method of reconstituting a lyophilized liposomal composition for administering cytarabine and daunorubicin to treat newly-diagnosed therapy-related aml (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in patients 1 year and older; Method of administering a reconstituted liposomal composition containing cytarabine and daunorubicin to treat newly-diagnosed therapy-related aml (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in patients 1 year and older; Method of administering a reconstituted liposomal composition containing cytarabine and daunorubicin to treat newly-diagnosed therapy-related aml (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in patients 1 year and older; method of reconstituting a lyophilized liposomal composition for administering cytarabine and daunorubicin to treat newly-diagnosed therapy-related aml (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in patients 1 year and older

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
100MG;44MG POWDER;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.